Cassini composite infrared spectrometer: correcting an offset error and refining the pointing parameters for the midinfrared detectors: publisher's note.

This publisher's note serves to correct Appl. Opt.62, 5882 (2023).

Cassini composite infrared spectrometer: correcting an offset error and refining the pointing parameters for the midinfrared detectors.

Based on preflight laboratory testing, an unexpectedly large positional offset between the two midinfrared (mid-IR) detector arrays in the Cassini composite infrared spectrometer (CIRS) instrument has been noted in the literature. A much smaller offset was measured in-flight. We investigate this discrepancy by estimating several spatial relationships among the detectors and comparing these results with three independent data sets.

Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.

Background: Radiation exposure from diagnostic imaging may increase cancer risk of Crohn's disease (CD) patients, who are already at increased risk of certain cancers.

Aim: To compare imaging radiation exposure and associated costs in CD patients during the year pre- and post-initiation of anti-tumor necrosis factor (anti-TNF) agents or corticosteroids.

Methods: Adults were identified from a large US claims database between 1/1/2005 and 12/31/2009 with ≥ 1 abdominal imaging scan and 12 months of enrollment before and after initiating therapy with anti-TNF or corticosteroids.

Characteristics of infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemia.

Aim: To evaluate factors associated with infection (CDI) and outcomes of CDI in the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) population.

Methods: After IRB approval, all MDS/AML patients hospitalized at the University of Maryland Greenebaum Comprehensive Cancer Center between August 2011 and December 2013 were identified. Medical charts were reviewed for demographics, clinical information, development of CDI, complications of CDI, and mortality.

Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs".

We previously concluded that 12 common excipients need not be qualitatively the same and quantitatively very similar to reference for Biopharmaceutics Classification System-based biowaivers. This conclusion for regulatory relief is based upon a series of bioequivalence studies in humans involving cimetidine and acyclovir. Limitations were also discussed.